文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

抗VEGF治疗后早产儿视网膜病变再激活的胎盘转录组分析

Placental Transcriptomic Analysis in Retinopathy of Prematurity Reactivation After Anti-VEGF Treatment.
PubMed 文献 · Am J Ophthalmol · 2025-07-30

该回顾性病例系列分析比较了接受0.2 mg雷珠单抗治疗后早产儿视网膜病变再激活组(n=4)与对照组(n=8)的胎盘转录组差异,鉴定出329个差异表达基因,其中9个枢纽基因的AUC>0.7,可能作为预测抗VEGF治疗后ROP再激活的潜在生物标志物。

要点

  • 再激活组鉴定出329个差异表达基因,其中207个上调、122个下调。
  • 15个枢纽基因均上调,与VEGFA-VEGF受体2信号及滋养层细胞表面抗原2调控信号相关。
  • 9个枢纽基因(ACTG1、BSG、ETS1、FN1、FOXO4、IGFBP3、NUMB、MDM2、SMARCA2)的AUC>0.7,提示高预测潜力。

核心结论

  • 再激活组母体胎盘中VEGFA-VEGF受体2信号通路相关基因显著上调,9个枢纽基因可能作为预测抗VEGF治疗后ROP再激活的潜在生物标志物。

研究设计与样本

  • 回顾性病例系列分析,纳入初始接受0.2 mg雷珠单抗治疗ROP且母体胎盘储存于人类资源库的早产儿,再激活组n=4、对照组n=8,行RNA测序鉴定差异表达基因。

主要发现

  • 再激活组鉴定出329个差异表达基因,包括207个上调基因和122个下调基因。
  • 15个枢纽基因均上调,与VEGFA-VEGF受体2信号及滋养层细胞表面抗原2调控信号相关。
  • 9个枢纽基因(ACTG1、BSG、ETS1、FN1、FOXO4、IGFBP3、NUMB、MDM2、SMARCA2)的AUC>0.7,提示高预测潜力。
  • 除FOXO4和SMARCA2外,其余7个枢纽基因与血管生成相关,包括VEGF通路和内皮细胞活性。

关键数值与推荐

  • 以ROC曲线≥0.7作为评估基因对ROP再激活预测潜力的标准。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study aimed to identify differentially expressed fetal factors in infants with reactivation of retinopathy of prematurity (ROP) using placental transcriptome analysis. DESIGN: This retrospective case series analyzed placental transcriptome differences between preterm infants with and without reactivation of ROP following anti-vascular endothelial growth factor (VEGF) treatment. METHODS: We enrolled preterm infants who initially received 0.2 mg of ranibizumab for the treatment of ROP and whose maternal placentas were stored at Human Resources Bank. RNA sequencing was performed to identify differentially expressed genes (DEGs) between reactivated ROP (n = 4) and control (n = 8) groups. Bioinformatics analyses included functional enrichment, protein-protein interaction network construction, and hub gene identification. To evaluate predictive potential for ROP reactivation, genes with an ROC curve ≥ 0.7 were considered. RESULTS: A total of 329 DEGs were identified in the reactivated ROP group, comprising 207 upregulated and 122 downregulated genes. Among them, 15 hub genes, all upregulated, were related to VEGFA-VEGF receptor 2 signaling and trophoblast cell surface antigen 2 regulatory signaling. Of these, 9 hub genes (ACTG1, BSG, ETS1, FN1, FOXO4, IGFBP3, NUMB, MDM2, and SMARCA2) showed an AUC > 0.7, indicating high predictive potential. Except for FOXO4 and SMARCA2, the remaining 7 were associated with angiogenesis, including the VEGF pathway and endothelial cell activity. CONCLUSIONS: Upregulation of genes involved in the VEGFA-VEGF receptor 2 signaling pathway was significantly identified in the maternal placentas of infants with reactivated ROP. These 9 hub genes may serve as potential biomarkers for predicting ROP reactivation following anti-VEGF therapy.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Kang J, Kim S, Bae JG, et al. Placental Transcriptomic Analysis in Retinopathy of Prematurity Reactivation After Anti-VEGF Treatment. Am J Ophthalmol. 2025. PMID: 40749864. doi:10.1016/j.ajo.2025.07.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。